| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3beb0bf66d7c1c7976c556d2c4684ac8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5050f8a78737ea730347d5e3d039fd0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-575 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_687dffaaf3e1af485aab171071e1813a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f1649ab183bb2965649cf510aecc92d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd7c666d5bf2ac9f4b6c4d676c12d83a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c9897f07b658bfee40199bf983cb660
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_002953c533e844064d76a15279b426ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67300538cdf8044545fa2fdec968ae0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4129d4c56c2813fcedb121d6f87b540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fd7df1793cc708876ed58a2ab3f5ffa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188a89d93e9112e61bd5849fcb25887f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0aa9c5f7ebf7b1828d6a6b9d685db26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68010bc06befb2940d7437b2d8752cb9 |
| publicationDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018109248-A1 |
| titleOfInvention |
Use of in1-ghrelin for the diagnosis of prostate cancer |
| abstract |
The present invention relates to a method for diagnosing and/or predicting cancer in a patient. In particular, the present invention relates to methods for diagnosing and/or predicting cancer that comprise: quantifying levels of In1-ghrelin expression in a plasma sample isolated from an individual; comparing the levels obtained with the levels of In1-ghrelin expression in a reference sample; and assigning the patients who show In1-ghrelin expression levels that are statistically significant and higher than the levels of the reference sample, to the group of individuals at risk of cancer. The present invention also provides a diagnostic method for bladder and/or colon cancer, which comprises quantifying expression levels of In1-ghrelin, GOAT and/or GHS-R1b in tissue samples. The present invention also relates to a small interfering RNA (siRNA) useful in a cancer treatment method. |
| priorityDate |
2016-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |